Maxwell Biosciences is proud to sponsor Longevity Biotech 2025, a rigorously science-driven meeting with a sharp focus on translational research, biotech innovation and commercial strategy. 📅 October 22–23, 2025 📍 Boston, MA As the longevity field moves from theory to translational therapeutics, innovators face challenges—regulatory ambiguity, a lack of validated biomarkers, complex trial design, high-risk investment landscapes and hype often outpacing clinical data. Longevity Biotech 2025 was created to tackle these barriers head-on. Guided by an advisory committee that includes experts from Rejuvenate Bio, Regeneron, Eli Lilly, Cambrian Bio and others, the meeting gathers leaders in biotech and pharma, investors and academic researchers to accelerate the path from discovery to the clinic. We invite you to join us in Boston. Learn more & register here: https://lnkd.in/eHv5BMWm #MaxwellBiosciences #LongevityBiotech2025 #AgingResearch #Longevity #BiotechInnovation
Maxwell Biosciences
Biotechnology Research
Austin, Texas 1,547 followers
Next Generation Anti-Infectives: A drug platform confirmed by independent labs to destroy all tested pathogenic microbes
About us
Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
- Website
-
https://maxwellbiosciences.com/
External link for Maxwell Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Austin, Texas
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
Austin, Texas, US
Employees at Maxwell Biosciences
-
Beth Burnside, Ph.D.
Sr. Vice President Research & Development Strategy
-
Jon McClure
Chief Technology Officer at Maxwell Biosciences
-
Joshua McClure
CEO @ Maxwell Biosciences - developing broad spectrum biodefense designed to extend healthspan by destroying viruses, fungi and bacteria with a…
-
Sarah Aubrey
Investor Relations; Complex & Strategic Project Planning
Updates
-
Some thoughts on what has become a national crisis in the USA from our founder, Scotch McClure.
CEO @ Maxwell Biosciences - developing broad spectrum biodefense designed to extend healthspan by destroying viruses, fungi and bacteria with a single molecule. One drug 💥 Many bugs.
As a CEO and Board Chairman, I’ve been reflecting deeply on the rising tide of political violence in our society, and I believe it’s time for us—as business leaders—to address it head-on with unity and resolve. Supporting or condoning acts of violence against any individual, regardless of their political views, is antithetical to the principles of a stable and prosperous nation. This includes recent discussions around figures like Charlie Kirk—violence has no place in our discourse. In the business world, we have the right—and often the responsibility—to make decisions that prioritize safety and ethical standards, including choosing partners and clients who align with non-violent values. This isn’t about exclusion; it’s about fostering environments where innovation and collaboration can thrive without fear. Fellow leaders: Whether you’ve voted Republican, Democrat, or independently (as I have), we must unite to reject political violence in all forms. We are not just executives; we are stewards of our communities and our country’s future. By promoting dialogue over division, we protect the economic stability that underpins our success. It’s clear that social media algorithms are amplifying extremes, pitting us against one another for engagement. But here on LinkedIn, I see a silent majority of center-left and center-right professionals who value safe, predictable business environments above all. Let’s not let extremists dictate the narrative. Instead, let’s commit to actions that build bridges: supporting civil discourse, investing in community safety, and holding our platforms accountable. Our leadership can make a real difference—starting today. What steps will you take? I’d welcome your thoughts in the comments.
-
It's hard to believe it, but it's already been almost a week since the 12th Aging Research & Drug Discovery Meeting! Maxwell was honored to sponsor this year's gathering in Copenhagen. The energy was electric—five days of bold ideas, big science and visionary partnerships at the world’s most scientifically influential longevity conference. Our COO and Head of R&D, Ed Rudnic, PhD, delivered a keynote on “Longevity Peptides, the Microbiome & the Gut-Brain Axis”, highlighting how Claromers® uniquely preserve the gut microbiome while targeting infectious disease. ➡️ Watch Ed's presentation: https://lnkd.in/eFReVkXK ➡️ Watch Ed's post-presentation interview: https://lnkd.in/ewpEFwJi #ARDD2025 #MaxwellBiosciences #DrugDiscovery #Microbiome #BiotechLeadership #LongevityScience
Longevity Peptides, the Microbiome and the Gut-Brain Axis, ARDD 2025
https://www.youtube.com/
-
Maxwell Biosciences is proud to be a Tier 1 sponsor of the 2025 Aging Research & Drug Discovery Meeting, the preeminent gathering in aging research and longevity therapeutics. Less than a week from now, our COO and Head of R&D, Ed Rudnic, PhD, will take the stage with his keynote: 🎤 Longevity Peptides, the Microbiome & the Gut-Brain Axis 📅 Mon., Aug. 25 | 14:40 - 15:00 CET / 8:40-9:00 a.m. EDT While the in-person event is sold out, virtual tickets are still available—a great opportunity to join the conversation and explore cutting-edge research from anywhere in the world: https://lnkd.in/eGShgRm5 Our team looks forward to connecting with fellow researchers, innovators and enthusiasts, and sharing insights that push the field of aging therapeutics forward. #ARDD2025 #AgingResearch #LongevityTherapeutics #MaxwellBiosciences #Microbiome
-
Today is Scientist Appreciation Day at Maxwell Biosciences. We started this as an internal company holiday to celebrate the people behind the breakthroughs that fuel our world. This year, we’re inviting you to join in. If you’re a scientist—working in a lab, teaching in a classroom, out in the field, or between jobs—we want to hear from you. Share your story. Share your work. We see you. 💡 For the rest of us: ➡️ Tag a scientist you admire (don’t forget: #WeAppreciateScientists) ➡️ Post a public thank-you ➡️ Support science—fund it, cite it, amplify it Read more about how we’re celebrating: https://lnkd.in/ezpfTjQT #WeAppreciateScientists #ScientistAppreciationDay #MaxwellBiosciences
-
-
With immense gratitude and excitement, Maxwell is proud to share we’ve closed our $20M financing round. As we prepare for FDA clinical trials and begin commercializing nonclinical Claromer™-based products, strong financial backing lets us move aggressively without hesitation. This raise allows us to: ▹ Prepare for clinical trials on schedule ▹ Scale manufacturing and regulatory frameworks ▹ Expand partnerships and commercial channels Read more here: https://lnkd.in/exFaN8ND
-
Maxwell is expanding its AI-first approach with the launch of a formal AI division focused on accelerating drug discovery and the development of AI-powered medical devices. As part of this initiative, Jon McClure has been named CTO to lead the company’s AI engineering strategy. “The future of medicine requires scalable intelligence, and Jon brings exactly that—combined with deeply human values,” said CEO, Founder & Chairman Joshua McClure. “Our AI division will serve as both accelerator and amplifier—driving faster drug design, analyzing clinical trial data and infusing every part of Maxwell with AI.” AI has been central to Maxwell’s work since its founding in 2016—designing molecules, modeling biology and streamlining operations in real time. This new division deepens that commitment, supporting scalable innovation across all areas of the business. 📍 Read the full announcement: https://lnkd.in/eCY5mG3D #MaxwellBiosciences #AI #DrugDiscovery #HealthTech #Claromers #CTO #BiotechLeadership #AIDivision
-
Join Maxwell Biosciences at Aging Research & Drug Discovery Meeting 2025—the premier global meeting for aging research and drug discovery. Our COO & Head of R&D Edward M. Rudnic, Ph.D. will present a keynote entitled: “Longevity Peptides, the Microbiome and the Gut-Brain Axis” This session will explore how immune-inspired peptide mimics may unlock new interventions at the intersection of microbial health, neurological function and longevity. For leaders in peptide innovation, neurobiology or microbiome science—this is one to watch. #Longevity #AgingResearch #GutBrainAxis #Microbiome #MaxwellBiosciences #ARDD2025 #DrugDiscovery #TranslationalScience August 25–29 | University of Copenhagen & Virtual Learn more at https://agingpharma.org
-
📢 Reminder: Join us at the 12th Annual Aging Research & Drug Discovery Meeting (ARDD 2025) from August 25-29 at the University of Copenhagen’s Ceremonial Hall or online. Our COO and Head of R&D, Edward M. Rudnic, Ph.D. will be speaking at this premier longevity conference, alongside global leaders like Nobel laureates Morten Meldal and Michael Levitt. Don’t miss the latest advancements in aging research and drug discovery. Secure your spot for virtual or in-person attendance at agingpharma.org. #ARDD2025 #AgingResearch #Longevity #MaxwellBiosciences
-
Today, Maxwell Biosciences announces strategic partnerships and licensing in cosmetics and personal care with our immune-inspired Claromer™ platform. Claromers™ are immune-inspired molecules designed to support the skin microbiome while providing broad-spectrum protection. -- Engineered for stability and safety -- Effective against bacteria, fungi, viruses and biofilms -- Compatible with the needs of modern skincare innovators We’re enabling a new era of microbiome-safe, science-backed personal care. 📣 Learn more and watch our announcement video: 🔗 https://lnkd.in/eb4TcjUZ #CosmeticsInnovation #MicrobiomeSafe #Licensing #Claromers #MaxwellBiosciences
-